I'll research MRNA before writing the preview. Let me start by gathering recent earnings materials, news, and stock data.MRNA has had a dramatic move — from ~$24 in late 2025 to a peak of ~$82 in early July 2026, now ~$54-58. Let me dig into what's driving this and read the most recent earnings materials.Now I have the key narrative. Let me read the Q1 2026 earnings call for management commentary and get the most recent July news to understand the pullback ahead of earnings.Let me get the most recent news and check analyst expectations ahead of the print.I now have a comprehensive picture. Let me write the preview.

Moderna (MRNA) — Q2 2026 Earnings Preview

Reports before the open, Friday July 31, 2026 (2026Q2 Earnings Call)

The one-line setup

This is a rare earnings report where the quarterly numbers are almost beside the point. Moderna has roughly tripled off its late-2025 lows on a pipeline-and-policy narrative (flu approval, a re-rated oncology franchise, and a splashy Investor Day), and the print itself will be a seasonally tiny, deeply loss-making quarter. The report is a placeholder ahead of the real catalyst three trading days later: the August 5 FDA PDUFA date for the mRNA-1010 flu vaccine. How management frames guidance, cash, and pipeline timing matters far more than the headline EPS.

Where the stock sits going in

MRNA closed ~$57.94 on 7/30, up ~96% from its 12/31/25 close of ~$29.49 (press reports peg it "82% higher YTD" depending on the reference point).
The move has been violent in both directions: shares ran to a ~$81.80 peak on July 6 (highest since August 2024) before a ~30% pullback over the last three weeks heading into the print.
Drivers of the run, in order of impact:
June 25 Investor Day — the surprise unveiling of Moderna's first in vivo CAR-T program (mRNA-6007, targeting B-cell autoimmune diseases like lupus, clinic in 2027) and a "three-horizons" pipeline framing. Jefferies flagged the potential for 7+ marketed products within two years.
Flu vaccine de-risking — a June FDA advisory committee voted unanimously that mRNA-1010's benefits outweigh risks in patients 50+, and briefing docs pointed toward approval.
Oncology optimism — anticipation of the Phase 3 adjuvant melanoma (intismeran) interim readout in 2H26.

The rally has left the sell-side sharply divided: bulls like Piper Sandler (~$77 PT, Overweight) versus skeptics like BofA (Underweight, $38 PT) and Morgan Stanley (Equal Weight, ~$39 PT), both of whom argue the stock has overshot the implied value of upcoming readouts. In other words, valuation now embeds a lot of pipeline success.

What to expect from the Q2 print itself

Revenue — expect a very small number. Management guided Q2 revenue of just $50–100M, versus published consensus that sits a touch higher (Zacks ~$126.7M; other aggregators ~$103M). Q2 is structurally the trough quarter for a respiratory-vaccine business, and management said Q2 sales are still primarily COVID (Spikevax/mNEXSPIKE), with RSV (mRESVIA) explicitly not a 2026 growth driver. Don't overreact to a small beat or miss on this line — the shape of the year is back-half loaded.

EPS — a large GAAP loss, distorted by the Arbutus settlement. Consensus is a loss of roughly $1.97–$2.07/share. Recall Q1 printed a GAAP loss of $(3.40) ($(1.18) ex the $878M litigation charge). Focus on the underlying/adjusted burn trajectory rather than the GAAP figure.

Cost discipline is the real P&L story. Q1 delivered a ~26% YoY reduction in adjusted cash cost. The full-year targets to hold management to: - FY26 adjusted cash costs ~$4.2B - R&D ~$3.0B (now weighted slightly to 2H) - SG&A ~$1.0B (also 2H-weighted on commercial seasonality)

The five things that actually move the stock

1. Flu (mRNA-1010) — PDUFA August 5. This overshadows the whole call. A U.S. approval would be Moderna's fifth product and a major sentiment win in a hostile mRNA-policy environment (the FDA notably refused, then reversed, the filing earlier in 2026). Listen for any tonal change on FDA interactions and post-approval commercial/ACIP positioning. Note: FY26 guidance assumes zero flu and zero mCOMBRIAX (flu+COVID combo) revenue, so approval is upside to the narrative, not the numbers, this year.

2. Adjuvant melanoma Phase 3 (intismeran/INT with Merck) interim — expected 2026. The single biggest fundamental catalyst. Management is "confident" the interim happens in 2026, there is no built-in futility (outcomes are "declare early success" or keep accruing), and they've framed a success range of hazard ratios "anywhere between ~0.5 and ~0.8." Any tightening of timing on this call is highly market-moving.

3. Norovirus (mRNA-1403) Phase 3 — fully enrolled in its second Northern Hemisphere season; data expected 2026 subject to case accrual. Bar is essentially statistical significance given no approved competitor; management wants efficacy north of 50%.

4. Propionic acidemia (mRNA-3927) — first rare-disease pivotal readout, expected 2026; would validate mRNA beyond vaccines.

5. Other INT reads (RCC, muscle-invasive bladder) — fully enrolled Phase 2s, event-driven, could land late-2026 or early-2027; watch for any timing color.

Guidance & balance-sheet watch items

FY26 revenue: "up to 10% growth" off 2025's ~$1.9B base, ~50/50 US/international. Reiteration is the base case after a strong, UK-partnership-driven Q1; any wobble here (e.g., softer US COVID demand or 2H UK fall-campaign timing) would be a negative.
Cash: guided to $4.5–5.0B at year-end 2026 (from $7.5B at 3/31/26), excluding a possible ~$0.9B credit-facility draw. Cash burn and runway is the perennial bear thesis — watch the updated year-end trajectory.
Arbutus/Genevant settlement: the $950M lump-sum payment hits in Q3 (this coming quarter). Also monitor commentary on the separate Section 1498 appeal, where an adverse ruling could mean up to an additional $1.3B (Moderna deems this "not probable," so nothing is accrued; resolution possibly late-2027/2028).

Risks / bear case to keep front of mind

Valuation has run ahead of de-risked fundamentals — the sharpest sell-side skeptics (BofA, MS) see ~40–50% downside to their targets; the 30% pre-print pullback shows how quickly momentum unwinds.
Policy overhang — an mRNA-skeptical HHS/RFK Jr. backdrop remains a wildcard for U.S. vaccine demand, recommendations, and reimbursement.
Structural COVID decline — the core revenue base is still shrinking COVID vaccines; 2027 EU launches (mNEXSPIKE, mCOMBRIAX) are the bridge but contribute little until 2027–2028.
New litigation — on July 15, Sanofi sued both Moderna and Pfizer over LNP/mRNA patents (Translate Bio IP), adding to an already crowded IP docket (though Sanofi says it isn't seeking to block sales).
Insider selling — President Stephen Hoge and others filed/executed planned sales into the June–July strength; worth noting for optics, though these appear to be pre-scheduled 10b5-1 sales.

Bottom line for investors

Expect a thin-revenue, wide-loss quarter that is unlikely to be the story. The bar for the actual print is low (company guided $50–100M), so the reaction will hinge on: (1) any read-through on the Aug 5 flu PDUFA and FDA relationship, (2) firmer timing/confidence on the melanoma Phase 3 interim and other 2026 readouts, and (3) reaffirmation of "up to 10%" revenue growth and the $4.5–5.0B year-end cash target. With the stock still up strongly YTD despite a recent 30% drawdown and a deeply split analyst base, positioning is fragile — a "clean reiteration + constructive flu commentary" is probably needed just to hold the line, while any slip on pipeline timing or cash could accelerate the pullback. The genuinely binary event is three days later, on August 5.

Sources: Moderna Q1 2026 earnings release and call transcript (5/1/26); company investor-day and press coverage (Barron's, Reuters, Zacks/TradingView, The Bull); consensus aggregators (Zacks, Benzinga); MRNA/PFE/BNTX price data through 7/30/26. Estimates and analyst targets are third-party and subject to revision.